睿知中国医院研究地图
候选清单

即将招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Adding Preoperative Radiotherapy Based on Early Treatment Response in Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由浙江大学医学院附属第二医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07892508,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. 2. Histologically confirmed unilateral invasive breast cancer with documented estrogen receptor, progesterone receptor, HER2, and Ki-67 status.

    入选标准第 2 条

    6. Suspicious or confirmed involved regional lymph nodes have undergone protocol-required pathological confirmation and marking when applicable.

    入选标准第 6 条

  3. 4. Nonmetastatic disease on a curative-intent pathway; clinical stage cT1c to cT4c and cN0 to cN3, excluding cT4d inflammatory breast cancer.

    入选标准第 4 条

  4. 3. No prior systemic therapy, radiotherapy, or definitive surgery for the current breast cancer.

    入选标准第 3 条

    2. Prior radiotherapy to the ipsilateral breast, chest wall, or regional lymph nodes when cumulative dose constraints cannot be met.

    排除标准第 2 条

  5. 5. At least one measurable breast primary tumor with a longest diameter of 15 mm or greater on baseline contrast-enhanced MRI; paired baseline BSGI and required lesion marking completed. Multifocal or multicentric disease must meet protocol imaging requirements.

    入选标准第 5 条

    8. Able and willing to comply with MRI, BSGI, treatment, follow-up, and contraception requirements. Participants of childbearing potential must have a negative pregnancy test before examinations involving a radiopharmaceutical.

    入选标准第 8 条

  6. 1. Distant metastatic disease, inflammatory breast cancer, or bilateral breast cancer requiring simultaneous definitive treatment.

    排除标准第 1 条

  7. 4. Pregnancy or breastfeeding, or inability to implement required contraception.

    排除标准第 4 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力;化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07892508,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 1.Age 18 to 75 years at the time of written informed consent.
  2. 2. Histologically confirmed unilateral invasive breast cancer with documented estrogen receptor, progesterone receptor, HER2, and Ki-67 status.
  3. 3. No prior systemic therapy, radiotherapy, or definitive surgery for the current breast cancer.
  4. 4. Nonmetastatic disease on a curative-intent pathway; clinical stage cT1c to cT4c and cN0 to cN3, excluding cT4d inflammatory breast cancer.
  5. 5. At least one measurable breast primary tumor with a longest diameter of 15 mm or greater on baseline contrast-enhanced MRI; paired baseline BSGI and required lesion marking completed. Multifocal or multicentric disease must meet protocol imaging requirements.
  6. 6. Suspicious or confirmed involved regional lymph nodes have undergone protocol-required pathological confirmation and marking when applicable.
  7. 7. ECOG performance status 0 or 1 and organ function adequate for planned systemic therapy, radiotherapy, and surgery.
  8. 8. Able and willing to comply with MRI, BSGI, treatment, follow-up, and contraception requirements. Participants of childbearing potential must have a negative pregnancy test before examinations involving a radiopharmaceutical.
  9. 9. A guideline-recommended, curative-intent neoadjuvant systemic therapy plan has been documented before entry. HER2-positive disease includes anti-HER2 therapy, and at least six cycles or the regimen-defined complete course is planned.

排除标准:Exclusion Criteria:

  1. 1. Distant metastatic disease, inflammatory breast cancer, or bilateral breast cancer requiring simultaneous definitive treatment.
  2. 2. Prior radiotherapy to the ipsilateral breast, chest wall, or regional lymph nodes when cumulative dose constraints cannot be met.
  3. 3. Active infection, interstitial lung disease, or another condition making planned standard therapy, research radiotherapy, or surgery unacceptably risky. Active autoimmune disease or organ transplantation is exclusionary only when contraindicated by the planned systemic-therapy component or considered an unacceptable risk by the multidisciplinary team.
  4. 4. Pregnancy or breastfeeding, or inability to implement required contraception.
  5. 5. Inability, in the investigator's judgment, to complete definitive surgery or key follow-up procedures.

引自 ClinicalTrials.gov, NCT07892508, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07892508,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07892508